BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-1402. [PMID: 22445239 DOI: 10.1016/s0140-6736(12)60324-9] [Cited by in Crossref: 695] [Cited by in F6Publishing: 122] [Article Influence: 77.2] [Reference Citation Analysis]
Number Citing Articles
1 Iannopollo G, Camporotondo R, De Ferrari GM, Leonardi S. Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Ther Clin Risk Manag 2014;10:321-9. [PMID: 24851050 DOI: 10.2147/TCRM.S39216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Remkes WS, Badings EA, Hermanides RS, Rasoul S, Dambrink JE, Koopmans PC, The SH, Ottervanger JP, Gosselink AT, Hoorntje JC, Suryapranata H, van 't Hof AW. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. Open Heart 2016;3:e000455. [PMID: 27933192 DOI: 10.1136/openhrt-2016-000455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Patil RK, Swaminathan RV, Feldman DN. Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal? Curr Atheroscler Rep 2015;17:63. [PMID: 26399876 DOI: 10.1007/s11883-015-0543-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Park DW, Ahn JM, Park SJ, Taggart DP. Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE-combined cardiology and cardiac surgery perspective. Ann Cardiothorac Surg 2018;7:521-6. [PMID: 30094217 DOI: 10.21037/acs.2018.04.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Gogas BD. Bioresorbable scaffolds for percutaneous coronary interventions. Glob Cardiol Sci Pract 2014;2014:409-27. [PMID: 25780795 DOI: 10.5339/gcsp.2014.55] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Zhang S, Zhang F, Feng B, Fan Q, Yang F, Shang D, Sui J, Zhao H. Hematopoietic stem cell capture and directional differentiation into vascular endothelial cells for metal stent-coated chitosan/hyaluronic acid loading CD133 antibody. Tissue Eng Part A 2015;21:1173-83. [PMID: 25404533 DOI: 10.1089/ten.TEA.2014.0352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
7 Wang QI, Zhou YU, Qiao T, Zhou M. Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up. Exp Ther Med 2015;9:1545-56. [PMID: 25780467 DOI: 10.3892/etm.2015.2293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Aksu U, Gulcu O, Aksakal E, Kalkan K, Öztürk M, Korkmaz AF, Uslu A, Demirelli S. The association between CRP / Albumin ratio and in-stent restenosis development in patients with ST-segment elevation myocardial infarction. J Clin Lab Anal 2019;33:e22848. [PMID: 30737841 DOI: 10.1002/jcla.22848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 De Meulder B, Berger F, Bareke E, Depiereux S, Michiels C, Depiereux E. Meta-analysis and gene set analysis of archived microarrays suggest implication of the spliceosome in metastatic and hypoxic phenotypes. PLoS One 2014;9:e86699. [PMID: 24497970 DOI: 10.1371/journal.pone.0086699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Iqbal J, Serruys PW, Taggart DP. Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol 2013;10:635-47. [PMID: 24042217 DOI: 10.1038/nrcardio.2013.138] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
11 Ljuca F, Hadžiefendić B, Jahić E, Tihić N, Lukić S. Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation. Saudi Med J 2019;40:1202-8. [PMID: 31828271 DOI: 10.15537/smj.2019.12.24737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes Based on the Hemoglobin A1c Level. J Interv Cardiol 2020;2020:1710439. [PMID: 32733169 DOI: 10.1155/2020/1710439] [Reference Citation Analysis]
13 Yang HM, Jin S, Jang H, Kim JY, Lee JE, Kim J, Kim HS. Sildenafil Reduces Neointimal Hyperplasia after Angioplasty and Inhibits Platelet Aggregation via Activation of cGMP-dependent Protein Kinase. Sci Rep 2019;9:7769. [PMID: 31123275 DOI: 10.1038/s41598-019-44190-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
14 Tocci G, Barbato E, Coluccia R, Modestino A, Pagliaro B, Mastromarino V, Giovannelli F, Berni A, Volpe M. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. Am J Hypertens 2016;29:509-18. [PMID: 26271109 DOI: 10.1093/ajh/hpv131] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
15 Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Clin Cardiol 2017;40:789-96. [PMID: 28683175 DOI: 10.1002/clc.22756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yoshikawa S, Ashikaga T, Miyazaki T, Kurihara K, Hirao K. Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. J Interv Cardiol 2019;2019:3146848. [PMID: 31777468 DOI: 10.1155/2019/3146848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gwon HC, Jeon DW, Kang HJ, Jang JS, Park DW, Shin DH, Moon KW, Kim JS, Kim J, Bae JW, Hur SH, Kim BO, Choi D, Han KR, Kim HS. The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. Korean Circ J 2017;47:320-7. [PMID: 28567082 DOI: 10.4070/kcj.2017.0070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
18 Camarero TG, de la Torre Hernández JM. Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. Eur Cardiol 2020;15:1-8. [PMID: 32180829 DOI: 10.15420/ecr.2019.25.2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Brodie BR, Pokharel Y, Garg A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey TD. Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16-year single-center experience. J Interv Cardiol 2014;27:21-8. [PMID: 24372979 DOI: 10.1111/joic.12082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
20 Shah R, Rao SV, Latham SB, Kandzari DE. Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis. JAMA Cardiol 2018;3:1050-9. [PMID: 30383145 DOI: 10.1001/jamacardio.2018.3551] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
21 Kočka V, Malý M, Toušek P, Buděšínský T, Lisa L, Prodanov P, Jarkovský J, Widimský P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J 2014;35:787-94. [PMID: 24419808 DOI: 10.1093/eurheartj/eht545] [Cited by in Crossref: 92] [Cited by in F6Publishing: 70] [Article Influence: 13.1] [Reference Citation Analysis]
22 Wu G, Sun G, Zhao R, Sun M. Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Arch Med Sci 2014;10:643-50. [PMID: 25276146 DOI: 10.5114/aoms.2014.44855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
23 Mori H, Atmakuri DR, Torii S, Braumann R, Smith S, Jinnouchi H, Gupta A, Harari E, Shkullaku M, Kutys R, Fowler D, Romero M, Virmani R, Finn AV. Very Late Pathological Responses to Cobalt-Chromium Everolimus-Eluting, Stainless Steel Sirolimus-Eluting, and Cobalt-Chromium Bare Metal Stents in Humans. J Am Heart Assoc 2017;6:e007244. [PMID: 29150493 DOI: 10.1161/JAHA.117.007244] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
24 Tang XF, Ma YL, Song Y, Xu JJ, Yao Y, He C, Wang HH, Jiang P, Jiang L, Liu R, Gao Z, Zhao XY, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovasc Diabetol 2018;17:114. [PMID: 30107794 DOI: 10.1186/s12933-018-0758-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Stefanini GG, Windecker S. Coronary stent choice in patients with acute myocardial infarction. Curr Cardiol Rep 2012;14:477-85. [PMID: 22581167 DOI: 10.1007/s11886-012-0281-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Santulli G. microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. Adv Exp Med Biol 2015;887:53-77. [PMID: 26662986 DOI: 10.1007/978-3-319-22380-3_4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
27 Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas M, Kornowski R, Bagur R, Iniguez A, Danenberg H, Feldman R, Jauhar R, Chandna H, Parikh M, Perlman GY, Balcells M, Markham P, Ozan MO, Genereux P, Edelman ER, Leon MB, Stone GW. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). Circulation 2017;136:1304-14. [PMID: 28794001 DOI: 10.1161/CIRCULATIONAHA.117.028885] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
28 Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793. [PMID: 30279197 DOI: 10.1136/bmj.k3793] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 22.3] [Reference Citation Analysis]
29 Xiao Y, Chen Z, Yang Y, Kou L. Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease. Diagn Interv Radiol 2016;22:436-43. [PMID: 27559766 DOI: 10.5152/dir.2016.15430] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Ijichi T, Nakazawa G, Torii S, Nagamatsu H, Yoshikawa A, Nakamura S, Souba J, Isobe A, Hagiwara H, Ikari Y. Late neointimal volume reduction is observed following biodegradable polymer-based drug eluting stent in porcine model. Int J Cardiol Heart Vasc 2021;34:100792. [PMID: 34036146 DOI: 10.1016/j.ijcha.2021.100792] [Reference Citation Analysis]
31 Yan P, Dong P, Li Z. Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis. Arch Med Sci 2014;10:213-21. [PMID: 24904652 DOI: 10.5114/aoms.2014.42571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Brancati MF, Burzotta F, Trani C, Leonzi O, Cuccia C, Crea F. Coronary stents and vascular response to implantation: literature review. Pragmat Obs Res 2017;8:137-48. [PMID: 28761388 DOI: 10.2147/POR.S132439] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016;315:1735-49. [PMID: 27022822 DOI: 10.1001/jama.2016.3775] [Cited by in Crossref: 514] [Cited by in F6Publishing: 379] [Article Influence: 102.8] [Reference Citation Analysis]
34 Sperling C, Waliszewski MW, Kherad B, Krackhardt F. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Ther Adv Cardiovasc Dis 2019;13:1753944719826335. [PMID: 30803407 DOI: 10.1177/1753944719826335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Kawecki D, Morawiec B, Dola J, Wanha W, Smolka G, Pluta A, Marcinkiewicz K, Ochała A, Nowalany-Kozielska E, Wojakowski W. First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry). Arq Bras Cardiol 2016;106:373-81. [PMID: 27058257 DOI: 10.5935/abc.20160043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
36 Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs 2017;77:1733-54. [PMID: 28853033 DOI: 10.1007/s40265-017-0806-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
37 Wang F, Su X, Liu C, Wu M, Li B. Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis. Med Sci Monit 2017;23:4733-9. [PMID: 28970468 DOI: 10.12659/msm.904352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
38 Liu R, Xiong F, Wen Y, Ma YL, Yao Y, Gao Z, Xu B, Yang YJ, Qiao SB, Gao RL, Yuan JQ. Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study. Chin Med J (Engl) 2017;130:1654-61. [PMID: 28685714 DOI: 10.4103/0366-6999.209904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Collet JP, Silvain J, Kerneis M, Cuisset T, Meneveau N, Boueri Z, Barthélémy O, Rangé G, Cayla G, Belle EV, Elhadad S, Carrié D, Caussin C, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; ARCTIC Investigators. Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. Clin Cardiol 2016;39:192-200. [PMID: 26880570 DOI: 10.1002/clc.22512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
40 Wang L, Wang H, Dong P, Li Z, Wang Y, Duan N, Zhao Y, Wang S. Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction. Arq Bras Cardiol 2014;102:529-38. [PMID: 25004414 DOI: 10.5935/abc.20140070] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
41 Watanabe H, Morimoto T, Natsuaki M, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kastrati A, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. PLoS One 2015;10:e0124314. [PMID: 25853836 DOI: 10.1371/journal.pone.0124314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
42 Mitchell AJ, Gillies MA, Cruden NL. Non-cardiac surgery following drug-eluting coronary stent implantation-a question of timing? J Thorac Dis 2017;9:E461-4. [PMID: 28616309 DOI: 10.21037/jtd.2017.04.45] [Reference Citation Analysis]
43 Zhang MD, Zhang YH, Zhu EJ, Qiao SB, Lv SZ, Zhao QM. Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e109614. [PMID: 25279761 DOI: 10.1371/journal.pone.0109614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Hong SJ, Ahn CM, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Her AY, Kim YH, Jang Y, Hong MK. Effect of Adjunct Balloon Dilation after Long Everolimus-eluting Stent Deployment on Major Adverse Cardiac Events. Korean Circ J 2017;47:694-704. [PMID: 28955388 DOI: 10.4070/kcj.2017.0016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
45 Meyers MW, Rink JS, Jiang Q, Kelly ME, Vercammen JM, Thaxton CS, Kibbe MR. Systemically administered collagen-targeted gold nanoparticles bind to arterial injury following vascular interventions. Physiol Rep 2017;5:e13128. [PMID: 28242820 DOI: 10.14814/phy2.13128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
46 Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol 2015;65:2211-21. [PMID: 25787199 DOI: 10.1016/j.jacc.2015.03.003] [Cited by in Crossref: 182] [Cited by in F6Publishing: 140] [Article Influence: 30.3] [Reference Citation Analysis]
47 Roever L, Biondi-Zoccai G. Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research. Arq Bras Cardiol 2016;106:333-7. [PMID: 27142793 DOI: 10.5935/abc.20160052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Pan C, Han Y, Lu J. Structural Design of Vascular Stents: A Review. Micromachines (Basel) 2021;12:770. [PMID: 34210099 DOI: 10.3390/mi12070770] [Reference Citation Analysis]
49 Kommineni N, Saka R, Khan W, Domb AJ. Non-polymer drug-eluting coronary stents. Drug Deliv Transl Res 2018;8:903-17. [PMID: 28799125 DOI: 10.1007/s13346-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
50 Nakazato K, Mizukami H, Ohtake H, Sakamoto N, Yamaki T, Yamaguchi O, Kunii H, Ohwada T, Takeishi Y. STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. Fukushima J Med Sci 2015;61:79-85. [PMID: 26135665 DOI: 10.5387/fms.2015-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Cho SC, Park DW, Park SJ. Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for the Treatment of Left Main Coronary Artery Disease. Korean Circ J 2019;49:369-83. [PMID: 31074210 DOI: 10.4070/kcj.2019.0112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Ullrich H, Münzel T, Gori T. Coronary Stent Thrombosis- Predictors and Prevention. Dtsch Arztebl Int 2020;117:320-6. [PMID: 32605709 DOI: 10.3238/arztebl.2020.0320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
53 Ziada KM, Abdel-Latif AK, Charnigo R, Moliterno DJ. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv 2016;87:722-32. [PMID: 26309050 DOI: 10.1002/ccd.26110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
54 Mahmoud AN, Shah NH, Elgendy IY, Agarwal N, Elgendy AY, Mentias A, Barakat AF, Mahtta D, David Anderson R, Bavry AA. Safety and efficacy of second-generation drug-eluting stents compared with bare-metal stents: An updated meta-analysis and regression of 9 randomized clinical trials. Clin Cardiol 2018;41:151-8. [PMID: 29369375 DOI: 10.1002/clc.22855] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Aoki J, Ikari Y. Cardiovascular Disease in Patients with End-Stage Renal Disease on Hemodialysis. Ann Vasc Dis 2017;10:327-37. [PMID: 29515692 DOI: 10.3400/avd.ra.17-00051] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
56 Ferko N, Ferrante G, Hasegawa JT, Schikorr T, Soleas IM, Hernandez JB, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Valgimigli M. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. Catheter Cardiovasc Interv 2017;89:994-1002. [PMID: 27527508 DOI: 10.1002/ccd.26700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
57 Dola J, Morawiec B, Wańha W, Nowalany-Kozielska E, Wojakowski W, Kawecki D. Results of PCI with Drug-Eluting Stents in an All-Comer Population Depending on Vessel Diameter. J Clin Med 2020;9:E524. [PMID: 32075153 DOI: 10.3390/jcm9020524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Jose RR, Raja WK, Ibrahim AM, Koolen PG, Kim K, Abdurrob A, Kluge JA, Lin SJ, Beamer G, Kaplan DL. Rapid prototyped sutureless anastomosis device from self-curing silk bio-ink. J Biomed Mater Res B Appl Biomater 2015;103:1333-43. [PMID: 25385518 DOI: 10.1002/jbm.b.33312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
59 Rief M, Feger S, Martus P, Laule M, Dewey M, Schönenberger E. Acceptance of Combined Coronary CT Angiography and Myocardial CT Perfusion versus Conventional Coronary Angiography in Patients with Coronary Stents--Intraindividual Comparison. PLoS One 2015;10:e0136737. [PMID: 26327127 DOI: 10.1371/journal.pone.0136737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation 2013;127:1861-9. [PMID: 23572500 DOI: 10.1161/CIRCULATIONAHA.112.001264] [Cited by in Crossref: 76] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
61 Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, Rowland SM, Tasissa G, Morrell D, Joseph D, Okaniwa Y, Shibata Y, Bertolet BD, Rothenberg MD, Généreux P, Bezerra H, Kong DF. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J 2018;39:2460-8. [PMID: 29931092 DOI: 10.1093/eurheartj/ehy275] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
62 Lehto HR, Pietilä A, Niiranen TJ, Lommi J, Salomaa V. Clinical practice patterns in revascularization of diabetic patients with coronary heart disease: nationwide register study. Ann Med 2020;52:225-32. [PMID: 32429711 DOI: 10.1080/07853890.2020.1771757] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Poder TG, Erraji J, Coulibaly LP, Koffi K. Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis. PLoS One 2017;12:e0177476. [PMID: 28498849 DOI: 10.1371/journal.pone.0177476] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
64 Caiazzo G, De Michele M, Golino L, Manganiello V, Fattore L. Sirolimus-Eluting Balloon for the Treatment of Coronary Lesions in Complex ACS Patients: The SELFIE Registry. J Interv Cardiol 2020;2020:8865223. [PMID: 33132769 DOI: 10.1155/2020/8865223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Herrmann J. Common Vascular Toxicities of Cancer Therapies. Cardiol Clin 2019;37:365-84. [PMID: 31587779 DOI: 10.1016/j.ccl.2019.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Nakamura K, Keating JH, Edelman ER. Pathology of Endovascular Stents. Interv Cardiol Clin 2016;5:391-403. [PMID: 28582036 DOI: 10.1016/j.iccl.2016.02.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
67 Ishihara T, Yamaji K, Iida O, Kohsaka S, Inohara T, Shinke T, Ando H, Amano T, Sakata Y, Mano T, Ikari Y. Impact of peripheral artery disease on short-term outcomes after percutaneous coronary intervention: A report from Japanese nationwide registry. PLoS One 2020;15:e0240095. [PMID: 33021993 DOI: 10.1371/journal.pone.0240095] [Reference Citation Analysis]
68 Habib A, Karmali V, Polavarapu R, Akahori H, Pachura K, Finn AV. Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis 2013;229:385-7. [PMID: 23880192 DOI: 10.1016/j.atherosclerosis.2013.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
69 Bahnson ES, Kassam HA, Moyer TJ, Jiang W, Morgan CE, Vercammen JM, Jiang Q, Flynn ME, Stupp SI, Kibbe MR. Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury. Antioxid Redox Signal 2016;24:401-18. [PMID: 26593400 DOI: 10.1089/ars.2015.6363] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
70 Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211-223. [PMID: 24163064 DOI: 10.1161/circulationaha.113.001790] [Cited by in Crossref: 326] [Cited by in F6Publishing: 100] [Article Influence: 40.8] [Reference Citation Analysis]
71 Takimura CK, Campos CA, Melo PH, Campos JC, Gutierrez PS, Borges TF, Curado L, Morato SP, Laurindo FR, Lemos Neto PA. Preclinical study of a biodegradable polymer-based stent with abluminal sirolimus release. Arq Bras Cardiol 2014;102:432-40. [PMID: 24759951 DOI: 10.5935/abc.20140044] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol 2017;2:855-62. [PMID: 28658478 DOI: 10.1001/jamacardio.2017.1978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
73 Carrabba N, Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Comito V, Bellandi B, Abbate R, Gensini GF, Antoniucci D. Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart 2016;3:e000460. [PMID: 27843564 DOI: 10.1136/openhrt-2016-000460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
74 Tantawy A, Ahn CM, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Med J 2017;58:290-5. [PMID: 28120558 DOI: 10.3349/ymj.2017.58.2.290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
75 Biondi-Zoccai G, Anderson LA. What is the purpose of launching World Journal of Meta-AnalysisWorld J Meta-Anal 2013; 1(1): 1-4 [DOI: 10.13105/wjma.v1.i1.1] [Reference Citation Analysis]
76 Beaulieu MC, Boivin-Proulx LA, Matteau A, Mansour S, Gobeil JF, Potter BJ. Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake. CJC Open 2021;3:1025-32. [PMID: 34505042 DOI: 10.1016/j.cjco.2021.04.002] [Reference Citation Analysis]
77 Yang Y, Park GM, Han S, Kim YG, Suh J, Park HW, Won KB, Ann SH, Kim SJ, Kim DW, Park MW, Her SH, Lee SG. Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a Korean nationwide study. PLoS One 2018;13:e0208746. [PMID: 30532214 DOI: 10.1371/journal.pone.0208746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
78 Cui K, Lyu S, Song X, Yuan F, Xu F, Zhang M, Wang W, Zhang D, Dai J. Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials. PLoS One 2017;12:e0176365. [PMID: 28445555 DOI: 10.1371/journal.pone.0176365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
79 Han S, Park GM, Kim YG, Park MW, Her SH, Lee SW, Kim YH. Trends, Characteristics, and Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention in Korea between 2011 and 2015. Korean Circ J 2018;48:310-21. [PMID: 29625513 DOI: 10.4070/kcj.2017.0359] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
80 Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, Sawan M, Sato Y, Cornelissen A, Kuntz SH, Kutyna M, Paek KH, Fernandez R, Braumann R, Mont EK, Surve D, Romero ME, Kolodgie FD, Virmani R, Finn AV. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J 2020;41:786-96. [PMID: 31803916 DOI: 10.1093/eurheartj/ehz850] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
81 Yeh RW, Mauri L, Kereiakes DJ. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol 2015;65:787-90. [PMID: 25720621 DOI: 10.1016/j.jacc.2015.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
82 Cho MS, Park DW. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. Korean J Intern Med 2017;32:769-79. [PMID: 28823143 DOI: 10.3904/kjim.2016.391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
83 Fujiu K, Manabe I, Sasaki M, Inoue M, Iwata H, Hasumi E, Komuro I, Katada Y, Taguchi T, Nagai R. Nickel-free stainless steel avoids neointima formation following coronary stent implantation. Sci Technol Adv Mater 2012;13:064218. [PMID: 27877545 DOI: 10.1088/1468-6996/13/6/064218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
84 Nakazawa G, Torii S, Ijichi T, Nagamatsu H, Ohno Y, Kurata F, Yoshikawa A, Nakano M, Shinozaki N, Yoshimachi F, Ikari Y. Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model. J Am Heart Assoc 2016;5:e003803. [PMID: 27792651 DOI: 10.1161/JAHA.116.003803] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
85 Garg S, Serruys PW. An update on drug-eluting stents. Curr Treat Options Cardiovasc Med 2013;15:61-78. [PMID: 23192748 DOI: 10.1007/s11936-012-0219-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Rozemeijer R, Voskuil M, Greving JP, Bots ML, Doevendans PA, Stella PR. Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. Neth Heart J 2018;26:242-51. [PMID: 29541996 DOI: 10.1007/s12471-018-1104-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Baschet L, Bourguignon S, Marque S, Durand-Zaleski I, Teiger E, Wilquin F, Levesque K. Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention. Open Heart 2016;3:e000445. [PMID: 27621830 DOI: 10.1136/openhrt-2016-000445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
88 Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Rabinowitz A, Carrié D, Pompili V, Bouchard A, Saito S, Allocco DJ, Dawkins KD, Stone GW. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial. JACC Cardiovasc Interv 2017;10:2392-400. [PMID: 29217001 DOI: 10.1016/j.jcin.2017.06.070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
89 Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, Yong C, Yu F, Yingchun B, Wangjun Y, Junbo G. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators Inflamm 2014;2014:963096. [PMID: 25538378 DOI: 10.1155/2014/963096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
90 Biondi Zoccai G, Abbate A, D'Ascenzo F, Presutti D, Peruzzi M, Cavarretta E, Marullo AG, Lotrionte M, Frati G. Percutaneous coronary intervention in nonagenarians: pros and cons. J Geriatr Cardiol 2013;10:82-90. [PMID: 23610578 DOI: 10.3969/j.issn.1671-5411.2013.01.013] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
91 Boivin-Proulx LA, Deneault-Marchand A, Matteau A, Mansour S, Gobeil F, Camm JA, Fox KAA, Potter BJ. Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. Clin Cardiol 2020;43:216-21. [PMID: 31850592 DOI: 10.1002/clc.23316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
92 Maupas E, Lipiecki J, Levy R, Faurie B, Karsenty B, Moulichon ME, Brunelle F, Maillard L, de Poli F, Lefèvre T. Safety and efficacy outcomes of 3rd generation DES in an all-comer population of patients undergoing PCI: 12-month and 24-month results of the e-Biomatrix French registry. Catheter Cardiovasc Interv 2017;90:890-7. [PMID: 28544186 DOI: 10.1002/ccd.27081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 de Franca JCQ, Godoy MF, Santos MA, Pivatelli FC, Neto WPG, De Souza Braite MR. Evaluation of the impact of chronic kidney disease on the survival of octogenarian patients submitted to percutaneous coronary intervention. Indian Heart J 2018;70:848-51. [PMID: 30580855 DOI: 10.1016/j.ihj.2018.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Sudhir K, Hermiller JB, Ferguson JM, Simonton CA. Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol 2013;2013:748736. [PMID: 23862074 DOI: 10.1155/2013/748736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
95 Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014;349:g6427. [PMID: 25378023 DOI: 10.1136/bmj.g6427] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
96 Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J 2015;169:222-233.e5. [PMID: 25641531 DOI: 10.1016/j.ahj.2014.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
97 Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034-43. [PMID: 28110296 DOI: 10.1093/eurheartj/ehw627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
98 Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res 2015;8:211-20. [PMID: 25986910 DOI: 10.1007/s12265-015-9632-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
99 Franzone A, Zaugg S, Piccolo R, Modena MG, Mikhail GW, Ferré JM, Strasser R, Grinfeld L, Heg D, Jüni P, Windecker S, Morice MC. A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS One 2017;12:e0182632. [PMID: 28796809 DOI: 10.1371/journal.pone.0182632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Husted S, Boersma E. Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Am J Ther 2016;23:e1876-89. [PMID: 25830867 DOI: 10.1097/MJT.0000000000000237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
101 Kim HK, Jeong MH. Coronary stent thrombosis: current insights into new drug-eluting stent designs. Chonnam Med J 2012;48:141-9. [PMID: 23323218 DOI: 10.4068/cmj.2012.48.3.141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
102 Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Igarashi K, Tanabe K, Kozuma K, Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016;31:196-209. [PMID: 26518420 DOI: 10.1007/s12928-015-0366-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
103 Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J, Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ; FREEDOM Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 2013;127:820-31. [PMID: 23277307 DOI: 10.1161/CIRCULATIONAHA.112.147488] [Cited by in Crossref: 86] [Cited by in F6Publishing: 20] [Article Influence: 9.6] [Reference Citation Analysis]
104 Fröhlich GM, Lansky AJ, Ko DT, Archangelidi O, De Palma R, Timmis A, Meier P. Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis. BMC Med 2013;11:123. [PMID: 23657123 DOI: 10.1186/1741-7015-11-123] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
105 Tada T, Kastrati A, Byrne RA, Schuster T, Cuni R, King LA, Cassese S, Joner M, Pache J, Massberg S, Schömig A, Mehilli J. Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. Int J Cardiovasc Imaging 2014;30:495-504. [PMID: 24452729 DOI: 10.1007/s10554-014-0376-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
106 Pellegrini DO, Gomes VO, Lasevitch R, Smidt L, Azeredo MA, Ledur P, Bodanese R, Sinnott L, Moriguchi E, Caramori P. Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol 2014;103:174-82. [PMID: 25098375 DOI: 10.5935/abc.20140110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
107 Katz G, Harchandani B, Shah B. Drug-eluting stents: the past, present, and future. Curr Atheroscler Rep 2015;17:485. [PMID: 25651784 DOI: 10.1007/s11883-014-0485-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
108 Zhang J, Carlin BP, Neaton JD, Soon GG, Nie L, Kane R, Virnig BA, Chu H. Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 2014;11:246-62. [PMID: 24096635 DOI: 10.1177/1740774513498322] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
109 Ijichi T, Nakazawa G, Torii S, Nagamatsu H, Yoshikawa A, Souba J, Isobe A, Hagiwara H, Ikari Y. Comparisons of early vascular reactions in biodegradable and durable polymer-based drug-eluting stents in the porcine coronary artery. PLoS One 2019;14:e0209841. [PMID: 30629613 DOI: 10.1371/journal.pone.0209841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
110 Yin Y, Zhang Y, Zhao X. Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials. PLoS One 2014;9:e99648. [PMID: 24945816 DOI: 10.1371/journal.pone.0099648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
111 Arishta Jhagroe D, Maria Ten Berg J. Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation. Interv Cardiol 2015;10:139-41. [PMID: 29588690 DOI: 10.15420/ICR.2015.10.03.139] [Reference Citation Analysis]
112 Kim CH, Han JK, Yang HM, Park KW, Lee HY, Kang HJ, Koo BK, Lee N, Cha TJ, Yang TH, Jeong MH, Yoon MH, Lee SU, Lee SJ, Kim JW, Cho JM, Han KR, Pyun WB, Kim HS. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. BMJ Open 2017;7:e016617. [PMID: 29025834 DOI: 10.1136/bmjopen-2017-016617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation 2017;135:1720-32. [PMID: 28228427 DOI: 10.1161/CIRCULATIONAHA.116.024835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
114 Brilakis ES, Banerjee S, Edson R, Shunk K, Goldman S, Holmes DR Jr, Bhatt DL, Rao SV, Smith MW, Sather M, Colling C, Kar B, Nielsen L, Conner T, Wagner T, Rangan BV, Ventura B, Lu Y, Holodniy M, Shih MC. Rationale and design of the Drug-Eluting Stents vs Bare-Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. Clin Cardiol 2017;40:946-54. [PMID: 28841230 DOI: 10.1002/clc.22763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
115 Tsai ML, Hsieh MJ, Chen CC, Chang SH, Wang CY, Chen DY, Yang CH, Yeh JK, Ho MY, Hsieh IC. Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. Acta Cardiol Sin 2020;36:97-104. [PMID: 32201459 DOI: 10.6515/ACS.202003_36(2).20190729A] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
116 Kwon SW, Park SD, Moon J, Oh PC, Jang HJ, Park HW, Kim TH, Lee K, Suh J, Kang W. Complete Versus Culprit-Only Revascularization for ST-Segment Elevation Myocardial Infarction and Multivessel Disease in the 2nd Generation Drug-Eluting Stent Era: Data from the INTERSTELLAR Registry. Korean Circ J 2018;48:989-99. [PMID: 30334385 DOI: 10.4070/kcj.2017.0387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Slater M, Bielecki J, Alba AC, Abrahamyan L, Tomlinson G, Mak S, MacIver J, Zieroth S, Lee D, Wong W, Krahn M, Ross H, Rac VE. Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis. Syst Rev 2019;8:40. [PMID: 30711016 DOI: 10.1186/s13643-019-0953-4] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
118 Kristensen SL, Galløe AM, Thuesen L, Kelbæk H, Thayssen P, Havndrup O, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Jeppesen JL. Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study. PLoS One 2014;9:e113399. [PMID: 25409336 DOI: 10.1371/journal.pone.0113399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Meng M, Gao B, Wang X, Bai ZG, Sa RN, Ge B. Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis. BMC Cardiovasc Disord 2016;16:34. [PMID: 26860585 DOI: 10.1186/s12872-016-0206-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
120 Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Intern Med 2020;180:420-8. [PMID: 31930361 DOI: 10.1001/jamainternmed.2019.6447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
121 Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013;347:f6530. [PMID: 24196498 DOI: 10.1136/bmj.f6530] [Cited by in Crossref: 159] [Cited by in F6Publishing: 118] [Article Influence: 19.9] [Reference Citation Analysis]
122 Doğan A, Kahraman S, Özdemir E, Kurtoğlu N. Prognostic value of high on-treatment platelet reactivity. Anatol J Cardiol 2017;17:250. [PMID: 28321100 DOI: 10.14744/AnatolJCardiol.2017.7665] [Reference Citation Analysis]